Atherosclerosis:低风险青年血压升高导致CAC负荷增加

2018-12-20 佚名 嘉音

在线发表于《atherosclerosis》杂志上的一项研究表明,即使是10年CVD风险处于低危的年轻人群,其较高的血压类别与较高的冠状动脉钙化(CAC)评分呈正相关。

在线发表于《atherosclerosis》杂志上的一项研究表明,即使是10年CVD风险处于低危的年轻人群,其较高的血压类别与较高的冠状动脉钙化(CAC)评分呈正相关。

美国心脏病学会和美国心脏协会(ACC/AHA)在新的高血压指南中给出的血压水平与低风险年轻人的亚临床冠状动脉粥样硬化之间的关系尚不清楚。该研究评估了新的血压分类在低风险的年轻和中年成人与CAC之间的关系。

研究者对96166例韩国人进行了横断面研究,这些人在2012~2017年接受了健康检查,包括心脏断层扫描评估CAC评分。 血压分类根据2017年ACC/AHA指南划分,采用泊松回归模型来计算CAC>0的流行率(PR)和95%置信区间(CI)。

总体而言,较高的血压类别与年轻人(20~39岁)和中年人(40岁或以上)较高的CAC评分相关。校正可能的混杂因素,包括传统血管疾病(CVD)风险因素后,血压升高、高血压1期和高血压2期与正常血压相比,其CAC的多变量校正PR(95% CI)分别为1.27(1.08~1.49),1.45 (1.28~1.63)和2.02 (1.67~2.43)。对于20~39岁的人群,其PR(95% CI)分别为1.25(1.15~1.36),1.29(1.23~1.35)和1.46(1.36~1.57)。在年龄≥40岁的人群中,这种关联在10年CVD风险<10%的患者中也很明显。

较高的血压类别与CAC呈正相关,随高血压类别升高,CAC负荷增加。并且这种关联在血压刚开始升高时即可出现,在年轻群体和低风险人群中都是如此。因此,即使在低风险的年轻人中也需要对高血压进行监测和管理

原始出处:
Jeonggyu Kang, Yoosoo Chang, Seolhye Kim. et al. Increased burden of coronary artery calcium from elevated blood pressure in low-risk young adults. Atherosclerosis. 1 December 2018. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1718947, encodeId=1d6a1e18947e4, content=<a href='/topic/show?id=32b888935ca' target=_blank style='color:#2F92EE;'>#血压升高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88935, encryptionId=32b888935ca, topicName=血压升高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c86e32676392, createdName=zhang92571, createdTime=Thu Jun 27 14:29:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947331, encodeId=5211194e33110, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Mar 07 14:29:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364430, encodeId=7366136443075, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541646, encodeId=bb88154164659, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355982, encodeId=6536355982de, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 21 00:40:13 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1718947, encodeId=1d6a1e18947e4, content=<a href='/topic/show?id=32b888935ca' target=_blank style='color:#2F92EE;'>#血压升高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88935, encryptionId=32b888935ca, topicName=血压升高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c86e32676392, createdName=zhang92571, createdTime=Thu Jun 27 14:29:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947331, encodeId=5211194e33110, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Mar 07 14:29:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364430, encodeId=7366136443075, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541646, encodeId=bb88154164659, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355982, encodeId=6536355982de, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 21 00:40:13 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1718947, encodeId=1d6a1e18947e4, content=<a href='/topic/show?id=32b888935ca' target=_blank style='color:#2F92EE;'>#血压升高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88935, encryptionId=32b888935ca, topicName=血压升高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c86e32676392, createdName=zhang92571, createdTime=Thu Jun 27 14:29:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947331, encodeId=5211194e33110, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Mar 07 14:29:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364430, encodeId=7366136443075, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541646, encodeId=bb88154164659, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355982, encodeId=6536355982de, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 21 00:40:13 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
    2018-12-22 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1718947, encodeId=1d6a1e18947e4, content=<a href='/topic/show?id=32b888935ca' target=_blank style='color:#2F92EE;'>#血压升高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88935, encryptionId=32b888935ca, topicName=血压升高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c86e32676392, createdName=zhang92571, createdTime=Thu Jun 27 14:29:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947331, encodeId=5211194e33110, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Mar 07 14:29:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364430, encodeId=7366136443075, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541646, encodeId=bb88154164659, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355982, encodeId=6536355982de, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 21 00:40:13 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1718947, encodeId=1d6a1e18947e4, content=<a href='/topic/show?id=32b888935ca' target=_blank style='color:#2F92EE;'>#血压升高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88935, encryptionId=32b888935ca, topicName=血压升高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c86e32676392, createdName=zhang92571, createdTime=Thu Jun 27 14:29:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947331, encodeId=5211194e33110, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Thu Mar 07 14:29:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364430, encodeId=7366136443075, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541646, encodeId=bb88154164659, content=<a href='/topic/show?id=0d9239585e' target=_blank style='color:#2F92EE;'>#CAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3958, encryptionId=0d9239585e, topicName=CAC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044f13304956, createdName=ms9651749636653578, createdTime=Sat Dec 22 12:29:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355982, encodeId=6536355982de, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Dec 21 00:40:13 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
    2018-12-21 医者仁心5538

    学习了

    0

相关资讯

阜外医院李建军等研究:血PCSK9水平能预测冠状动脉钙化程度

伸指一数,促进冠状动脉钙化的因素好像很多。近期阜外医院血脂异常与心血管病中心李建军、曹晔萱等进行的研究则提示,血浆前蛋白转化酶枯草杆菌蛋白酶kexin 9 型(PCSK9)对冠状动脉钙化具有潜在的促进作用。

Circulation:对于普通健康中年男性,心肺适应性越好,心血管意外风险越低

一篇极具说服力的文献表明冠状动脉钙化(CAC)和心肺适应性(CRF)都是心血管疾病(CVD)事件的独立预测因子。但目前我们对CRF和CAC关于CVD风险的相互联系知之甚少。CAC高时,CRF高相比CRF低与CVD事件减少相关。Nina B. Radford等人故开展一项研究,在CAC负担增加的背景下,对CRF持续水平对CVD风险的影响进行评估。研究人员共研究了8425位无临床CVD的男性,其于19

JCEM:冠状动脉钙化与糖基化血红蛋白指数的关联性研究

背景:糖基化血红蛋白,英文名为Glycosylated hemoglobin or glycated hemoglobin(GHb),是血红蛋白的一种形式,用于反映一段时间(4-8周)前的平均血浆葡萄糖浓度。糖基化血红蛋白指数(The hemoglobin glycation index,HGI)与心血管疾病风险相关。目的:本研究旨在通过4年以上的观察分析没有糖尿病的参与者中冠状动脉钙化(CAC)

Heart:冠状动脉钙化预测冠状动脉疾病的性别差异!

在传统的预测变量基础上增加CAC,可显著改善疑似冠心病患者的危险分类,性别差异影响了其预测能力。

JACC Cardiovasc Imag:CAC评分可更好地预测符合他汀治疗标准患者的风险

对于符合他汀治疗试验证据的患者,冠状动脉钙化(CAC)评分能否进一步增加风险预测价值尚不清楚。近期,JACC Cardiovasc Imaging发表的一项最新研究对此问题进行了探讨。

Med Sci Sports Exerc:马拉松男子运动员与冠状动脉钙化

长期跑马拉松的男子冠状动脉钙化(CAC)评分增加与心血管风险是否存在相关性尚不清楚。近期发表的一项最新研究就此问题进行了探讨。